Is BGLC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BGLC. It does not provide personalized investment advice.

BGLC (BioNexus Gene Lab Corp Common stock) Stock Analysis - Financials

BioNexus Gene Lab Corp Common stock (BGLC) is a publicly traded Healthcare sector company. As of May 29, 2026, BGLC trades at $2.32 with a market cap of $5.80M and a P/E ratio of 0.00. BGLC moved -7.92% today. Year to date, BGLC is -39.24%; over the trailing twelve months it is -34.07%. Its 52-week range spans $1.92 to $15.60. Rallies surfaces BGLC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are BGLC's key financials?

BGLC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BGLC recently traded at $2.32. Market cap is $5.80M. P/E ratio is 0.00. Revenue is $7.42M.

BGLC Key Metrics

Key financial metrics for BGLC
Metric	Value
Price	$2.32
Market Cap	$5.80M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$15.60
52-Week Low	$1.92
Volume	211.90K
Avg Volume	0
Revenue (TTM)	$7.42M
Net Income	$-2.98M
Gross Margin	14.62%

BGLC Analyst Consensus

BGLC analyst coverage data. Average price target: $0.00.

Common questions about BGLC

What are BGLC's key financials?: BGLC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BGLC recently traded at $2.32. Market cap is $5.80M. P/E ratio is 0.00. Revenue is $7.42M.
Is BGLC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BGLC. It does not provide personalized investment advice.